You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Investigational Drug Information for Tavapadon


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Tavapadon?

Tavapadon is an investigational drug.

There have been 9 clinical trials for Tavapadon. The most recent clinical trial was a Phase 1 trial, which was initiated on October 27th 2020.

The most common disease conditions in clinical trials are Parkinson Disease, Renal Insufficiency, and Liver Diseases. The leading clinical trial sponsors are Cerevel Therapeutics, LLC and [disabled in preview].

There are eleven US patents protecting this investigational drug and seventy-nine international patents.

Recent Clinical Trials for Tavapadon
TitleSponsorPhase
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's DiseaseCerevel Therapeutics, LLCPhase 1
Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult ParticipantsCerevel Therapeutics, LLCPhase 1
To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic FunctionCerevel Therapeutics, LLCPhase 1

See all Tavapadon clinical trials

Clinical Trial Summary for Tavapadon

Top disease conditions for Tavapadon
Top clinical trial sponsors for Tavapadon

See all Tavapadon clinical trials

US Patents for Tavapadon

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tavapadon ⤷  Subscribe Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY) ⤷  Subscribe
Tavapadon ⤷  Subscribe Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (New York, NY) ⤷  Subscribe
Tavapadon ⤷  Subscribe Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY) ⤷  Subscribe
Tavapadon ⤷  Subscribe 1,5-naphthyridine derivatives and MELK inhibitors containing the same OncoTherapy Science, Inc. (Kanagawa, JP) ⤷  Subscribe
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tavapadon

Drugname Country Document Number Estimated Expiration Related US Patent
Tavapadon Argentina AR096748 2033-06-27 ⤷  Subscribe
Tavapadon Australia AU2014300673 2033-06-27 ⤷  Subscribe
Tavapadon Brazil BR112015030101 2033-06-27 ⤷  Subscribe
Tavapadon Canada CA2916653 2033-06-27 ⤷  Subscribe
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.